Gosset research
Reports
Catalyst forecasts, competitive landscapes, conference coverage, worked examples and research articles, newest first. Every item links to the report itself.
Landscapes
The programs, evidence and deals around a target or disease.
Landscape
Huntington’s disease: search and evaluation
A screen of the assets in development for Huntington’s disease, with the context to weigh their potential.
Landscape
Claudin 18.2 research landscape
Source-linked programs, patient populations, clinical results and rights across antibodies, ADCs and cell therapies.
Undated
Landscape
TL1A research landscape
TL1A biology in inflammatory bowel disease, the Merck, Roche and Sanofi-Teva Phase 3 race, clinical evidence, patents and deals.
Undated
Catalysts
Forecasts of a trial’s chance of success, ahead of its readout.
Catalyst
Halneuron: ahead of Phase 2b results
A Gosset PTRS forecast for chemotherapy-induced neuropathic pain, with comparable trials and the evidence behind the estimate.
Conferences
Key results and trends from medical meetings, by therapeutic area.
Conference
ASH 2026: hematology readouts
55 selected hematology readouts, with highlights, efficacy and safety charts, patient settings and original sources. Abstract-release preview.
Conference
ESMO 2026: oncology readouts
Explore clinical results, ADC programs and emerging oncology approaches, with source-linked charts and trial context.
Conference
Cardiology conferences
Key results and trends from 1 meeting: ESC.
Conference
Dermatology conferences
Key results and trends from 2 meetings: EADV, AAD.
Conference
Endocrinology & Metabolism conferences
Key results and trends from 3 meetings: ENDO, ADA, EASD.
Conference
Gastroenterology conferences
Key results and trends from 3 meetings: DDW, AASLD, EASL.
Conference
Hematology conferences
Key results and trends from 2 meetings: ASH, EHA.
Conference
Immunology conferences
Key results and trends from 3 meetings: EULAR, ACR, AAAAI.
Conference
Nephrology conferences
Key results and trends from 2 meetings: ASN, ERA.
Conference
Neurology conferences
Key results and trends from 2 meetings: AAN, ECTRIMS.
Conference
Oncology conferences
Key results and trends from 10 meetings: AACR, ASCO, ESMO, WCLC, SITC, ASCO GU, ASCO GI, ESMO Asia, ESMO GI, ELCC.
Conference
Ophthalmology conferences
Key results and trends from 2 meetings: ARVO, EURETINA.
Conference
Pulmonology conferences
Key results and trends from 3 meetings: ATS, ERS, CHEST.
Worked examples
Research questions answered with Gosset, step by step.
Worked example
Phase 1 trials of B7-H3-targeted drugs
Every Phase 1 and Phase 1/2 trial of a B7-H3-directed drug, with modality, tumour type, geography and status.
Worked example
Claudin 18.2 competitive landscape
Claudin 18.2 programs from preclinical to approval, with program profiles, trial sources and licensing context.
Worked example
China-to-US ADC licensing
China-origin ADCs in Phase 2 or 3 and their US licensing partners, with phases and downloadable data.
Research articles
Assessments of individual assets and market questions.
Research article
DT120: off-patent LSD, reworked into a $4.4B psychiatry bet
Definium’s single-dose lysergide after a strong GAD Phase 2b and a positive MDD Phase 3: the moat, modeled odds and rNPV.
Research article
Most of XBI’s +78% is sector beta, not new money
A factor model and deal-flow data split the small-cap biotech index’s one-year run, leaving M&A the one outside-money channel.
Research article
Tegoprubart: a CNI-free bet on tolerability in kidney transplant
Eledon’s anti-CD40L antibody missed its Phase 2 efficacy endpoint yet separated sharply from tacrolimus on safety.
Reports
Asset, disease and clinical reports, including sample deliverables.
Report
HCXT-2001: oral IL-23R inhibition
Inside the oral IL-23R program behind Gilead’s announced acquisition agreement: mechanism, clinical evidence and competition.
Report · External · Slide deck
Asset due diligence: Frexalimab for relapsing multiple sclerosis (opens Slide deck on Google Drive)
Full due-diligence assessment of a drug asset: thesis, evidence, competitive landscape, IP, pricing, and risks.
External sample
Report · External · Slide deck
Disease brief: IgA nephropathy (opens Slide deck on Google Drive)
A business development brief for a disease: unmet need, epidemiology, pipeline & competition, deals, and risk.
External sample